---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-028621"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2023-06-16T23:59:59+00:00"
generated_at: "2026-06-13T22:55:47.896644+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Arcus Biosciences annual meeting results and revised director comp: $45k retainer, $750k initial equity

## Summary
- All four director nominees elected; Ernst & Young ratified as auditor; say-on-pay approved with ~92% for.
- Board revised non-employee director compensation: annual cash retainer $45,000; additional committee chair retainers up to $25,000.
- Initial equity award ~$750,000 (2/3 options, 1/3 RSUs) with 3-year vesting; annual award ~$400,000 with 12-month or next meeting vesting.
- Compensation changes effective June 15, 2023, as detailed in Exhibit 10.1.

## SEC filing metadata
- accession: 0000950170-23-028621
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2023-06-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000095017023028621/0000950170-23-028621-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000095017023028621/rcus-20230615.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-028621
- JSON: https://secwatch.observer/filing/0000950170-23-028621.json
- Plain text: https://secwatch.observer/filing/0000950170-23-028621.txt

## Key facts
- Shareholder Votes
  Arcus Biosciences, Inc. shareholders approved Advisory approval of named executive officer compensation at the 2023-06-15 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-15
  source text: Proposal 3 : The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement: Votes For Votes Against Abstentions Broker Non-Votes 56,058,305 2,350,776 50,777 8,655,281
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000095017023028621/0000950170-23-028621-index.htm
- Shareholder Votes
  Arcus Biosciences, Inc. shareholders approved Election of directors at the 2023-06-15 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-15
  source text: Proposal 1 : The election of a director to hold office until the 2026 Annual Meeting of Stockholders and until its successor is duly elected and qualified: Nominee Votes For Votes Withheld Broker Non-Votes Dr. David Lacey 40,854,980 17,604,878 8,655,281 Dr. Juan Jaen 43,694,709 14,765,149 8,655,281 Dr. Merdad Parsey 42,680,149 15,779,709 8,655,281 Ms. Nicole Lambert 46,262,513 12,197,345 8,655,281
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000095017023028621/0000950170-23-028621-index.htm
- Shareholder Votes
  Arcus Biosciences, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-15 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-15
  source text: Proposal 2 : The ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023: Votes For Votes Against Abstentions 65,921,166 1,127,268 66,708
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000095017023028621/0000950170-23-028621-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.